Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758729 | 1.00 | FABP5 (0.39) | FABP5EPHX2FABP7MAPTKDM4E | |
| SCHEMBL18961416 | 0.87 | EPHX2 (0.36) | FABP5EPHX2FABP7MAPTKDM4E | |
| SCHEMBL18939951 | 0.83 | RORC (0.37) | FABP5EPHX2FABP7KMT2A | |
| SCHEMBL18939766 | 0.82 | FABP5 (0.41) | FABP5EPHX2FABP7KMT2AACE | |
| SCHEMBL18940037 | 0.79 | RORC (0.40) | FABP5EPHX2FABP7KMT2A | |
| SCHEMBL30951904 | 0.73 | ACE (0.54) | FABP5EPHX2FABP7KMT2ATSHR | |
| SCHEMBL21899390 | 0.73 | ACE (0.54) | FABP5EPHX2FABP7KMT2ATSHR | |
| SCHEMBL3366520 | 0.73 | ACE (0.54) | FABP5EPHX2FABP7KMT2ATSHR | |
| SCHEMBL18940070 | 0.72 | RORC (0.55) | — | |
| SCHEMBL13259983 | 0.72 | ACE (0.43) | FABP5EPHX2FABP7KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453644-B1 | Compounds | ASTRAZENECA, AB (SE) | 2022-09-27 | — | — | US | disclosed |
| EP-3390396-B1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-06 | — | — | EP | disclosed |
| CN-109071516-B | Novel compounds | 阿斯利康(瑞典)有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10988445-B2 | Compounds | ASTRAZENECA AB (SE) | 2021-04-27 | — | — | US | disclosed |
| US-20200181084-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2020-06-11 | — | — | US | disclosed |
| US-10526286-B2 | Compounds | ASTRAZENECA AB (SE) | 2020-01-07 | — | — | US | disclosed |
| US-20190084934-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-03-21 | — | — | US | disclosed |
| EP-3390396-A1 | ISOINDOLE COMPOUNDS | Astrazeneca AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| US-10011566-B2 | Compounds | ASTRAZENECA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011566-B2 | Compounds | ASTRAZENECA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| WO-2017102784-A9 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017102784-A1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102784-A1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | disclosed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | disclosed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453644-B1 | Compounds | RORC, RORB, RORA | FABP5 1400/4885EPHX2 1604/4885FABP7 1679/4885 |
| US-10526286-B2 | Compounds | RORC, RORB, RORA | FABP5 1400/4885EPHX2 1604/4885FABP7 1679/4885 |
| US-10988445-B2 | Compounds | RORC, RORB, RORA | FABP5 1400/4885EPHX2 1604/4885FABP7 1679/4885 |
| US-10011566-B2 | Compounds | RORC, RORB, RORA | FABP5 1400/4885EPHX2 1604/4885FABP7 1679/4885 |
| US-20200181084-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | FABP5 1309/4885EPHX2 1977/4885FABP7 1374/4885 |
| US-20190084934-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | FABP5 1309/4885EPHX2 1977/4885FABP7 1374/4885 |
| US-20170166527-A1 | Novel Compounds | RORC, RORB, RORA | FABP5 1309/4885EPHX2 1977/4885FABP7 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.